Biodexa Pharmaceuticals Plc: Form 6-K Summary (Period Ended June 30, 2024)
Business Context and Reporting Period
This Form 6-K reports the unaudited interim results for Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) for the six months ended June 30, 2024. Biodexa is a clinical-stage biopharmaceutical company focused on acquiring and developing innovative products for diseases with unmet medical needs. The reporting period highlights the strategic licensing of eRapa, a Phase 3-ready asset for Familial Adenomatous Polyposis (FAP), and progress in its pipeline for Type 1 diabetes (tolimidone) and brain cancers (MTX110).
Key Financial Metrics
| Metric | 1H 2024 | 1H 2023 |
|---|---|---|
| Revenue | £0.00 million | £0.30 million |
| Net Loss | £3.31 million | £3.57 million |
| R&D Costs | £2.19 million | £2.25 million |
| Administrative Costs | £2.03 million | £2.29 million |
| Cash Used in Operating Activities | £4.81 million | £3.88 million |
| Cash Balance (June 30, 2024) | £5.06 million | £5.23 million |
| Accumulated Deficit | £147.88 million | £139.65 million |
Liquidity and Debt: The company holds £5.06 million in cash and cash equivalents. Total liabilities stood at £5.24 million, including £2.01 million in deferred consideration related to the eRapa license and £1.16 million in derivative financial liabilities (warrants).
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero from £0.30 million in 1H23 as the R&D collaboration with Janssen concluded in September 2023.
- Cost Reductions: R&D costs decreased by 3% (£0.06 million) due to reduced spend on the MAGIC-G1 study and termination of legacy projects, partially offset by new costs for tolimidone and eRapa. Administrative costs fell 11% (£0.26 million) driven by foreign exchange reversals and lower professional fees.
- Financing Activity: The company raised £4.74 million net from share issuances and warrant exercises in 1H24, compared to £6.35 million in 1H23. This included a warrant inducement in May 2024 raising $6.05 million gross.
- Intangible Assets: Significant increase in intangible assets to £6.01 million (from £2.94 million) due to the acquisition of the eRapa license.
Guidance, Outlook, and Risks
Operational Outlook: Management plans to execute on lead programs, including a Phase 3 registrational study of eRapa in FAP, with recruitment expected to begin early next year. A Phase 2a study of tolimidone in Type 1 diabetes has received Health Canada approval.
Going Concern Uncertainty: The filing contains a material uncertainty regarding the company's ability to continue as a going concern. Directors forecast cash will fund operations only into the first quarter of 2025. Failure to secure additional funding before then could result in administration.
Listing Risk: On August 27, 2024, Nasdaq notified the company of non-compliance with the minimum bid price requirement ($1.00). The company has requested a hearing to stay delisting. Additionally, a reverse stock split (ratio change) is effective October 4, 2024, changing the ADS ratio from 1:400 to 1:10,000.
Post-Period Events: In July 2024, the company raised an additional $5.0 million via a Registered Direct Offering. In September 2024, the company completed the final match payment to unlock the remaining $17 million CPRIT grant for the eRapa Phase 3 study.
Investor Verification Checklist
- Cash Runway: Verify the timeline for securing additional financing before Q1 2025 to avoid administration.
- Nasdaq Compliance: Monitor the outcome of the hearing regarding the minimum bid price delisting notice and the impact of the upcoming reverse stock split.
- eRapa Grant Funding: Confirm the disbursement schedule of the $17 million CPRIT grant following the September 2024 match payment.
- Dilution Risk: Assess the impact of recent and potential future equity financings (warrant exercises, registered direct offerings) on shareholder dilution.
- Clinical Milestones: Track the initiation of the eRapa Phase 3 study and the readout of the tolimidone Phase 2a study.